CJC-1295 Peptide Research: 7 Key Findings on GHRH Receptors, DAC Modification and Growth Hormone Signaling
An evidence-based guide to the long-acting GHRH analogue CJC-1295, albumin-binding chemistry, human pharmacokinetics, growth hormone pulsatility, IGF-1 responses and the limitations of clinical evidence.
CJC-1295 peptide research examines a synthetic analogue of growth hormone-releasing hormone (GHRH) developed to produce prolonged stimulation of the pituitary growth hormone axis.
The compound attracted scientific attention because of its distinctive Drug Affinity Complex (DAC) modification, which allows the peptide to associate with circulating albumin and remain active for substantially longer than unmodified GHRH.
Published human studies demonstrated prolonged increases in circulating growth hormone (GH) and insulin-like growth factor 1 (IGF-1). However, those studies were relatively small and focused primarily on endocrine measurements rather than long-term clinical outcomes.
An important complication is the inconsistent terminology used outside scientific publications. The original CJC-1295 investigated in clinical trials contains an albumin-binding DAC component. Products described as “CJC-1295 without DAC” generally refer to a different GHRH analogue, commonly called modified GRF(1–29).
These substances should not automatically be treated as chemically or pharmacologically equivalent.
CJC-1295 peptide research also raises questions about prolonged endocrine stimulation, glucose regulation, immunogenicity and cardiovascular responses. The US Food and Drug Administration has identified significant safety concerns and limitations in the available human evidence.
This guide examines seven major scientific findings, explains the underlying mechanisms and distinguishes established laboratory observations from unsupported claims about body composition, athletic performance and anti-aging effects.
1. CJC-1295 Peptide Research: Molecular Structure and Chemical Identity
CJC-1295 is a modified analogue of the biologically active N-terminal region of human GHRH.
Its development involved changes to the peptide sequence and the addition of an albumin-binding chemical component.
Molecular specifications
| Property | Scientific information |
|---|---|
| Compound | CJC-1295 with DAC |
| Research classification | Long-acting GHRH analogue |
| Peptide backbone | Modified GRF(1–29) |
| Principal structural feature | Drug Affinity Complex (DAC) |
| DAC chemistry | Maleimide-containing albumin-binding group |
| Principal receptor | Growth hormone-releasing hormone receptor |
| Main signaling pathway | Gs–adenylyl cyclase–cAMP |
| Major research endpoints | GH, IGF-1 and pharmacokinetics |
| Published human evidence | Small controlled endocrine studies |
| FDA-approved medicine | No |
| Principal terminology concern | Confusion with modified GRF(1–29) without DAC |
How does CJC-1295 differ from natural GHRH?
Natural GHRH is a hypothalamic hormone that stimulates growth hormone secretion.
Its relatively short biological persistence creates limitations for sustained experimental stimulation.
CJC-1295 incorporates chemical modifications intended to increase stability and prolong exposure.
What is modified GRF(1–29)?
Modified GRF(1–29) is a synthetic analogue based on the first 29 amino acids of GHRH.
Several residues are substituted to change its biochemical characteristics.
Is modified GRF(1–29) the same as CJC-1295?
Not when CJC-1295 refers to the original DAC-containing compound.
The albumin-binding modification changes the molecule’s chemical identity and pharmacokinetic behavior.
Why is naming consistency important?
CJC-1295 peptide research requires precise identification of the material used in an experiment.
A paper examining DAC-containing CJC-1295 cannot automatically establish the pharmacokinetics of a non-DAC peptide.
What about molecular formula and molecular weight?
Different sources may report values for the DAC-containing compound, a non-DAC analogue, different chemical forms or an albumin-bound species.
Researchers should verify the precise structural definition before assigning a molecular formula or mass.
Scientific interpretation
CJC-1295 is not simply another name for every modified GHRH fragment.
Its original scientific identity includes the DAC modification.
2. CJC-1295 Peptide Research and the Drug Affinity Complex
The DAC modification is central to the compound’s research history.
What does DAC mean?
DAC stands for Drug Affinity Complex.
It describes a chemical approach designed to extend the persistence of a therapeutic molecule through association with a circulating protein.
Why use albumin?
Albumin is a major protein found in blood plasma.
It has a comparatively long circulating lifespan and participates in the transport of numerous endogenous and exogenous substances.
How does the DAC component work?
The original CJC-1295 contains a reactive chemical group designed to form a covalent bond with albumin.
This changes how the peptide behaves in circulation.
Is the interaction simply weak reversible binding?
No.
The original DAC design involves covalent albumin association, which differs from ordinary reversible protein binding.
Does albumin binding change receptor specificity?
Albumin binding primarily influences pharmacokinetic behavior.
It does not mean that albumin itself becomes the growth hormone-releasing hormone receptor.
What is pharmacokinetics?
Pharmacokinetics describes how a substance is absorbed, distributed, metabolized and eliminated.
Why is prolonged exposure scientifically important?
A longer-lived compound may stimulate biological pathways over an extended period.
This can change both the duration of a desired pharmacological response and the potential duration of adverse effects.
Does a longer half-life guarantee a better treatment?
No.
A longer half-life may be useful for certain experimental or clinical objectives, but it can also complicate control of exposure.
What about the non-DAC version?
A peptide without the albumin-binding group should not be assigned the same prolonged half-life merely because it is marketed under a similar name.
Scientific interpretation
CJC-1295 peptide research demonstrates how chemical modification can alter peptide pharmacokinetics.
The DAC component is a defining feature of the original long-acting molecule.
3. CJC-1295 Peptide Research and GHRH Receptor Signaling
CJC-1295 acts through the GHRH receptor, which is expressed by pituitary somatotroph cells.
What is the GHRH receptor?
The growth hormone-releasing hormone receptor is a class B G protein-coupled receptor.
Its activation contributes to the regulation of endogenous growth hormone secretion.
What are somatotroph cells?
Somatotrophs are specialized cells in the anterior pituitary responsible for producing and releasing growth hormone.
How does receptor activation work?
GHRH receptor stimulation engages intracellular signaling pathways, particularly those associated with the stimulatory G protein Gs.
What happens to cyclic AMP?
Activation of adenylyl cyclase increases intracellular cyclic adenosine monophosphate, or cAMP.
What does cAMP do?
cAMP participates in downstream signaling that influences cellular activity, hormone synthesis and secretion.
Does CJC-1295 act directly on the growth hormone receptor?
No.
Its primary pharmacological action occurs at the GHRH receptor.
The growth hormone receptor is a separate downstream component of the endocrine system.
How does this differ from recombinant growth hormone?
Recombinant growth hormone acts directly as a growth hormone receptor ligand.
CJC-1295 stimulates endogenous hormone secretion through an upstream receptor.
Is pituitary function necessary?
The pharmacological response depends on responsive pituitary tissue.
The effects cannot be assumed to be identical in people with different forms of pituitary dysfunction.
Scientific interpretation
CJC-1295 peptide research provides a model for examining prolonged upstream stimulation of the GH axis.
Its receptor mechanism should not be confused with direct growth hormone replacement.
4. CJC-1295 Peptide Research: Human GH and IGF-1 Findings
The best-known clinical investigation was published by Teichman and colleagues in The Journal of Clinical Endocrinology & Metabolism in 2006.
What was the study design?
The investigators conducted two randomized, double-blind, placebo-controlled ascending-exposure studies.
The studies lasted 28 and 49 days.
Who participated?
The studies included healthy adults between 21 and 61 years of age.
What did the researchers measure?
The primary endpoints included circulating growth hormone, IGF-1 and pharmacokinetic parameters.
What happened to growth hormone?
The researchers reported dose-dependent increases in mean plasma GH concentrations.
After a single exposure, mean GH concentrations increased approximately twofold to tenfold for six days or longer.
What happened to IGF-1?
Mean IGF-1 concentrations increased approximately 1.5-fold to threefold for nine to eleven days.
What was the estimated half-life?
The reported estimated half-life was approximately 5.8–8.1 days.
What happened after repeated exposure?
Mean IGF-1 concentrations remained above baseline for up to 28 days in the multiple-exposure study.
What about serious adverse reactions?
The authors reported no serious adverse reactions during these particular studies.
Does that establish long-term safety?
No.
Short-duration trials involving limited numbers of participants cannot establish comprehensive long-term safety.
Does increased GH prove improved physical performance?
No.
The studies primarily measured hormone responses.
They did not establish clinically meaningful improvements in muscle strength, endurance, fat loss or longevity.
Scientific interpretation
CJC-1295 peptide research demonstrates prolonged endocrine activity in healthy adults.
The results establish pharmacodynamic effects, not broad therapeutic effectiveness.
5. CJC-1295 Peptide Research and Growth Hormone Pulsatility
A second 2006 study examined whether prolonged stimulation altered the pulsatile nature of growth hormone secretion.
What is pulsatile secretion?
Growth hormone is normally released in episodes rather than at a constant rate.
This pattern reflects complex regulation by hypothalamic and pituitary signals.
Why study pulsatility?
The timing and pattern of hormone secretion can influence biological responses.
What did the researchers examine?
The investigators collected frequent blood samples overnight before and after CJC-1295 exposure.
They examined growth hormone pulse characteristics and downstream IGF-1 responses.
What happened to growth hormone pulses?
The study reported that pulsatile secretion persisted despite prolonged GHRH receptor stimulation.
Did pulse frequency increase?
The investigators did not observe significant changes in pulse frequency.
Did pulse amplitude increase?
The study did not identify a significant change in pulse amplitude.
What changed?
Basal or trough GH concentrations increased substantially.
The study reported an approximately 7.5-fold increase in trough concentrations.
What happened to mean GH?
Mean growth hormone concentrations increased by approximately 46%.
What happened to IGF-1?
IGF-1 concentrations increased by approximately 45%.
Does preserved pulsatility prove normal endocrine regulation?
No.
A preserved pulsatile pattern does not establish that all aspects of endocrine physiology remain unchanged. CJC-1295 peptide research
Why is the finding important?
The study suggests that sustained GHRH receptor stimulation can increase overall hormone exposure without eliminating detectable secretory pulses.
Scientific interpretation
CJC-1295 peptide research indicates that prolonged receptor stimulation can coexist with pulsatile GH secretion.
This does not establish that prolonged exposure is physiologically harmless.
6. CJC-1295 Peptide Research: Clinical Applications and Evidence Gaps
CJC-1295 has been discussed in relation to growth hormone deficiency, body composition, aging and metabolic health.
However, the evidence supporting these proposed applications differs substantially from the evidence supporting hormone stimulation. CJC-1295 peptide research
Has CJC-1295 demonstrated biological activity in humans?
Yes.
Controlled studies documented increases in GH and IGF-1.
Has it been approved for growth hormone deficiency?
No.
CJC-1295 is not an FDA-approved treatment for growth hormone deficiency. CJC-1295 peptide research
Does it increase muscle mass?
The published human endocrine studies do not establish clinically meaningful improvements in muscle mass or strength. CJC-1295 peptide research
Does it reduce body fat?
A rise in growth hormone does not independently demonstrate a reduction in visceral or total body fat.
Does it improve sleep?
The available human evidence does not establish CJC-1295 as a treatment for insomnia or poor sleep quality.
What about aging?
There is no reliable clinical evidence demonstrating that CJC-1295 reverses biological aging or extends human lifespan. CJC-1295 peptide research
Can tesamorelin trial results be applied to CJC-1295?
No.
Tesamorelin is a distinct GHRH analogue with its own molecular structure, clinical development program and approved indication.
What about combination research?
Some commercial descriptions discuss combining CJC-1295 with ghrelin receptor agonists such as ipamorelin.
However, the effects and safety of such combinations cannot be inferred simply by adding together the findings for each compound. CJC-1295 peptide research
What is the central evidence gap?
The most important missing evidence concerns meaningful clinical outcomes and long-term safety.
Scientific interpretation
CJC-1295 peptide research supports endocrine pharmacology but not claims of established benefits for muscle growth, weight loss, sleep improvement or longevity.
7. CJC-1295 Peptide Research: Safety and FDA Regulatory Concerns
The safety evidence for CJC-1295 is limited.
The FDA has specifically reviewed concerns associated with CJC-1295-related bulk drug substances.
Is CJC-1295 FDA-approved?
No.
There is no FDA-approved CJC-1295 medicine. CJC-1295 peptide research
What has the FDA identified?
The FDA has identified potential immunogenicity concerns, challenges involving peptide-related impurities and limitations in active pharmaceutical ingredient characterization.
What serious adverse events have been identified?
The FDA has identified reports involving increased heart rate and systemic vasodilatory reactions.
What is a vasodilatory reaction?
Vasodilation refers to widening of blood vessels. CJC-1295 peptide research
Systemic vasodilatory responses may be associated with changes in blood pressure and other cardiovascular symptoms.
What about other reported adverse effects?
FDA review materials discuss injection-site reactions, headache, nausea, abdominal discomfort, diarrhea, dizziness, hypotension and other symptoms.
Does the absence of serious adverse events in the 2006 trials prove safety?
No.
The early trials were too small and short to exclude uncommon or delayed adverse effects.
What is immunogenicity?
Immunogenicity refers to the potential of a substance to provoke an immune response.
Why is immunogenicity relevant?
Modified peptides and their associated impurities may raise questions about antibody formation and other immune responses.
What about long-term IGF-1 elevation?
Prolonged changes in GH–IGF-1 signaling require careful evaluation because these hormones influence metabolism and cellular growth. CJC-1295 peptide research
Are research materials equivalent to approved medicines?
No.
Research materials should not be represented as FDA-approved pharmaceutical products.
Scientific interpretation
CJC-1295 peptide research has identified meaningful pharmacological activity, but long-term clinical safety remains inadequately established.
The FDA’s concerns should be considered alongside the published endocrine findings.
CJC-1295 Peptide Research: Evidence Summary
| Research question | Evidence available | Appropriate conclusion |
|---|---|---|
| GHRH analogue identity | Chemical and pharmacological literature | Modified GHRH-related peptide |
| DAC albumin binding | Mechanistic research | Defining feature of original CJC-1295 |
| GHRH receptor activation | Established pharmacology | Upstream GH-axis stimulation |
| Increased GH | Small controlled human studies | Demonstrated |
| Increased IGF-1 | Small controlled human studies | Demonstrated |
| Prolonged half-life | Human pharmacokinetic research | Approximately 5.8–8.1 days |
| Preserved GH pulsatility | Small human mechanistic study | Reported |
| Muscle strength | Insufficient clinical evidence | Not established |
| General fat loss | Insufficient clinical evidence | Not established |
| Human anti-aging effects | Insufficient clinical evidence | Not established |
| Long-term safety | Limited human evidence | Uncertain |
| FDA approval | Regulatory status | Not approved |
Worked Example: Interpreting Growth Hormone and IGF-1 Data
Consider a hypothetical laboratory dataset comparing endocrine measurements at baseline and follow-up.
The figures below are fictional and illustrate how results should be interpreted. CJC-1295 peptide research
| Measurement | Baseline | Follow-up | Relative change |
|---|---|---|---|
| Mean GH | 1.5 ng/mL | 4.5 ng/mL | 3-fold |
| IGF-1 | 150 ng/mL | 225 ng/mL | 1.5-fold |
| Fasting glucose | 92 mg/dL | 98 mg/dL | Approximately 6.5% increase |
What does the table suggest?
The hypothetical dataset shows increases in GH, IGF-1 and fasting glucose.
Does it prove receptor specificity?
No.
The receptor mechanism requires separate pharmacological evidence.
Does it demonstrate improved body composition?
No.
No body-composition endpoint is included. CJC-1295 peptide research
Is the glucose change clinically meaningful?
That cannot be determined from the table alone.
Interpretation requires the study population, variability, measurement conditions and clinical context.
Does an increase in IGF-1 establish benefit?
No.
A biomarker response does not independently establish better health.
Main lesson
CJC-1295 peptide research must distinguish endocrine pharmacodynamics from clinically meaningful outcomes and safety.
CJC-1295 Laboratory Testing: Identity, Purity and Stability
Reliable CJC-1295 peptide research requires more than a label stating the compound name. CJC-1295 peptide research
DAC versus non-DAC identity
The first analytical question is whether the material contains the albumin-binding DAC modification.
A non-DAC GHRH analogue should not be represented as the original CJC-1295 studied in human trials.
Molecular mass
Mass spectrometry can help establish whether the measured mass is consistent with the intended compound.
However, accurate interpretation requires knowledge of the complete molecular structure.
Sequence verification
Sequence-related impurities, truncations and substitutions can affect chemical identity. CJC-1295 peptide research
DAC-related characterization
The albumin-binding chemical component should be accounted for in the analytical specification.
HPLC purity
High-performance liquid chromatography can separate the target peptide from selected impurities.
Peak-area percentage is not identical to absolute peptide content.
LC-MS analysis
Liquid chromatography–mass spectrometry combines chromatographic separation with mass-based detection.
It can support identity testing and selected impurity investigations. CJC-1295 peptide research
Albumin-binding assays
A functional albumin-binding experiment may provide additional information about DAC-related behavior.
However, such an assay does not replace chemical identity testing.
Counterions and water content
A peptide preparation may contain counterions, water or other constituents that affect total material mass.
Stability
Stability depends on chemical structure, formulation and environmental conditions.
Storage and shelf-life claims require material-specific evidence. CJC-1295 peptide research
Batch documentation
A meaningful Certificate of Analysis should identify the material, batch, analytical methods and results.
Sterility and endotoxins
Chemical purity and molecular identity do not establish sterility or endotoxin status. CJC-1295 peptide research
Separate testing is necessary where relevant.
Scientific interpretation
CJC-1295 peptide research requires particularly careful analytical characterization because the DAC/non-DAC naming problem can affect the interpretation of nearly every experimental result.
CJC-1295 Compared With Other Growth Hormone Research Peptides
| Compound | Principal mechanism | Main distinction |
|---|---|---|
| CJC-1295 with DAC | GHRH receptor agonist | Albumin-binding modification and prolonged exposure |
| Modified GRF(1–29) without DAC | GHRH receptor agonist | Lacks original DAC albumin-binding component |
| Sermorelin | GHRH receptor agonist | GHRH(1–29) analogue |
| Tesamorelin | GHRH receptor agonist | Modified 44-residue analogue with a specific FDA-approved indication |
| Ipamorelin | Ghrelin receptor agonist | Different receptor pathway |
| GHRP-2 | Ghrelin receptor agonist | Different receptor pathway and pharmacology |
| Recombinant human growth hormone | Growth hormone receptor agonist | Acts downstream of GHRH receptor stimulation |
Why do these differences matter?
Peptides that influence the same endocrine axis may have different structures, receptor interactions and pharmacokinetics.
Are their clinical findings interchangeable?
No.
Each compound requires its own evidence for safety and clinical effectiveness.
Related Axion Peptide Lab research guides
Peptide Structure–Activity Relationships
These internal URLs are proposed editorial links and should be verified before publication.
CJC-1295 Research Materials at Axion Peptide Lab
Axion Peptide Lab provides a catalogue relevant to laboratory peptide research.
Researchers studying GHRH receptor signaling should review current catalogue information and available technical documentation.
What should laboratories verify?
The most important distinction is whether the intended research material contains the DAC modification.
Additional specifications include chemical identity, molecular mass, batch number and analytical methods.
Why does the DAC distinction matter?
It affects the relationship between molecular structure and expected pharmacokinetic behavior.
Does a high HPLC purity percentage establish biological potency?
No.
Chemical purity does not independently establish receptor activity or albumin-binding performance.
Can a research vial be treated as an approved medicine?
No.
Research materials are not automatically pharmaceutical products and should not be represented as approved for human administration.
Frequently Asked Questions About CJC-1295 Peptide Research
1. What is CJC-1295 peptide research?
CJC-1295 peptide research examines a modified GHRH analogue developed to produce prolonged growth hormone and IGF-1 responses.
2. What does DAC mean in CJC-1295?
DAC means Drug Affinity Complex. It refers to the albumin-binding chemical modification associated with the original long-acting compound.
3. Is CJC-1295 without DAC the same compound?
No. Products described as CJC-1295 without DAC commonly refer to modified GRF(1–29), which lacks the defining albumin-binding component.
4. Does CJC-1295 stimulate growth hormone?
Yes. Published human studies reported sustained increases in circulating growth hormone.
5. Does CJC-1295 increase IGF-1?
Yes. Early controlled human studies reported increases in IGF-1 concentrations.
6. What is the reported half-life of CJC-1295?
The original human pharmacokinetic study estimated a half-life of approximately 5.8–8.1 days for the DAC-containing compound.
7. Does CJC-1295 preserve growth hormone pulsatility?
A small human mechanistic study reported that GH secretion remained pulsatile during prolonged stimulation.
8. Is CJC-1295 FDA-approved?
No. CJC-1295 is not an FDA-approved medicine.
9. Does CJC-1295 improve muscle growth or fat loss?
The available human endocrine studies do not establish reliable clinical benefits for muscle growth or general fat loss.
10. How can laboratories verify CJC-1295 quality?
Relevant methods include structural identity testing, HPLC, LC-MS, DAC-specific characterization and batch-specific analytical documentation.
Conclusion: What CJC-1295 Peptide Research Establishes
CJC-1295 peptide research provides a well-documented example of how chemical modification can prolong the biological activity of a peptide hormone analogue.
The original DAC-containing compound was developed to associate with circulating albumin and extend exposure.
Controlled human studies reported sustained increases in GH and IGF-1, with an estimated half-life of 5.8–8.1 days.
A separate study found that growth hormone secretion remained pulsatile despite prolonged stimulation.
These results establish meaningful endocrine activity, but they do not prove improved muscle strength, fat loss, sleep quality or human longevity.
The distinction between CJC-1295 with DAC and modified GRF(1–29) without DAC is essential for accurate scientific interpretation.
Long-term safety also remains uncertain, and the FDA has identified concerns involving adverse cardiovascular reactions, immunogenicity and peptide characterization.
For laboratories, precise chemical identity, appropriate analytical testing and careful interpretation of endocrine measurements remain fundamental.
The strongest conclusion is that CJC-1295 is a long-acting experimental GHRH analogue with demonstrated human pharmacodynamic activity, but without an established FDA-approved therapeutic indication.
Scientific References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.
https://doi.org/10.1210/jc.2005-1536 - Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797.
https://doi.org/10.1210/jc.2006-1702 - US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks - US Food and Drug Administration. (2024). Pharmacy Compounding Advisory Committee meeting materials: CJC-1295 safety and characterization.
https://www.fda.gov/media/183891/download - ClinicalTrials.gov. CJC-1295 clinical research records.
https://clinicaltrials.gov/search?term=CJC-1295 - PubMed. Growth hormone-releasing hormone receptor signaling literature.
https://pubmed.ncbi.nlm.nih.gov/?term=growth+hormone+releasing+hormone+receptor+signaling - PubMed. CJC-1295 pharmacokinetics and human endocrine studies.
https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+pharmacokinetics - PubMed. Growth hormone pulsatility and IGF-1 physiology.
https://pubmed.ncbi.nlm.nih.gov/?term=growth+hormone+pulsatility+IGF-1
These references support the scientific discussion. They do not verify the identity, purity, safety or clinical suitability of independently supplied research materials.
Research-use notice: This article is intended for scientific education and legitimate laboratory research. Axion Peptide Lab research materials are not intended for human or veterinary administration. CJC-1295 is not an FDA-approved medicine. Experimental findings should not be interpreted as medical advice, administration guidance or established claims of therapeutic benefit.